Analysts grow more bullish on BioMarin Pharmaceuticals Inc. (BMRN) after Amicus acquisition
I'm PortAI, I can summarize articles.
BioMarin Pharmaceuticals Inc. is acquiring Amicus Therapeutics for $4.8 billion in an all-cash transaction, paying $14.50 per share. This acquisition is expected to strengthen BioMarin's position in the gene editing sector, as analysts rank it second among the most promising gene editing stocks.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments